Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Paolo Strati,Mohamed Amin Ahmed,Loretta J. Nastoupil,Lei Feng,Fredrick B. Hagemeister,Luis Fayad,Maria A. Rodriguez,Felipe Samaniego,Michael Wang,Jason R. Westin,Hun J. Lee,Swaminathan Padmanabhan Iyer,Simrit Parmar,Sairah Ahmed,Ranjit Nair,Raphael E Steiner,Mansoor Noorani,Christopher R. Flowers,R. Eric Davis,Nathan Fowler,Sattva S. Neelapu

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

2020

AbstractIn 2 randomized phase 3 trials BR resulted in longer progression-free survival (PFS) than frontline R-CHOP in patients with indolent and mantle cell lymphoma. However, in subset analyses of...

Keywords:

Gastroenterology
Immunology
CHOP
Internal medicine
Diabetes mellitus
Medicine
Oncology
Mantle cell lymphoma
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations